1 Medicus Economics , Milton, Massachusetts.
2 AbbVie, Inc. , North Chicago, Illinois.
J Womens Health (Larchmt). 2018 Oct;27(10):1204-1214. doi: 10.1089/jwh.2017.6752. Epub 2018 Aug 7.
Women with uterine fibroids (UF) may undergo less invasive procedures than hysterectomy, including myomectomy, endometrial ablation (EA), and uterine artery embolization (UAE); however, long-term need for reintervention is not well characterized. We estimated reintervention rates for 5 years and identified predictors of reintervention.
A longitudinal retrospective cohort study was conducted in women in MarketScan Commercial Claims and Encounters (Truven Health Analytics) aged 18-49 years with UF diagnosis before myomectomy, EA, or UAE from 2008 to 2014. Patients were categorized by initial procedure (index date) and required to have ≥12 months of continuous coverage before and after. Kaplan-Meier analyses and Cox proportional hazard models were used to estimate survival without reintervention and hazard of reintervention for 5 years.
The study included 35,631 women with myomectomy (n = 13,804: 8,018 abdominal, 941 hysteroscopic, and 4,845 laparoscopic), EA (n = 17,198), and UAE (n = 4,629). Myomectomy had the lowest 12-month reintervention rate (4.2%), followed by UAE (7.0%), then EA (12.4%; both p < 0.001 relative of myomectomy). Estimates of 5-year reintervention rates were 19% for myomectomy (17%, 28%, and 20% for abdominal, hysteroscopic, and laparoscopic, respectively), 33% for EA, and 24% for UAE. EA and UAE had adjusted hazard ratios of 2.63 (95% confidence interval [CI], 2.44-2.83) and 1.56 (95% CI, 1.42-1.72). Prior anemia, bleeding, pelvic inflammatory disease, and abdominal and pelvic pain increased the hazard of reintervention.
Reintervention rate estimates ranged from 17% to 33% for 5 years after myomectomy, EA, and UAE for patients with UF. Risk of requiring reintervention should be considered during treatment selection.
患有子宫肌瘤(UF)的女性可能会接受比子宫切除术创伤更小的治疗,包括子宫肌瘤切除术、子宫内膜消融术(EA)和子宫动脉栓塞术(UAE);然而,长期需要再次干预的情况尚未得到很好的描述。我们评估了 5 年内的再次干预率,并确定了再次干预的预测因素。
在 MarketScan 商业索赔和就诊记录(Truven Health Analytics)中,进行了一项纵向回顾性队列研究,该研究纳入了 2008 年至 2014 年间年龄在 18 至 49 岁之间、接受过子宫肌瘤切除术、EA 或 UAE 治疗的 UF 患者。根据初始治疗(索引日期)将患者分类,并要求在治疗前后至少有 12 个月的连续覆盖。使用 Kaplan-Meier 分析和 Cox 比例风险模型来估计 5 年内无需再次干预的生存率和再次干预的风险。
研究纳入了 35631 名接受子宫肌瘤切除术(n=13804:8018 例剖腹、941 例宫腔镜和 4845 例腹腔镜)、EA(n=17198)和 UAE(n=4629)治疗的女性。子宫肌瘤切除术的 12 个月再次干预率最低(4.2%),其次是 UAE(7.0%),其次是 EA(12.4%;与子宫肌瘤切除术相比均 P<0.001)。子宫肌瘤切除术、EA 和 UAE 的 5 年再次干预率估计值分别为 19%(17%、28%和 20%,分别为剖腹、宫腔镜和腹腔镜)、33%和 24%。EA 和 UAE 的调整后风险比分别为 2.63(95%置信区间[CI],2.44-2.83)和 1.56(95%CI,1.42-1.72)。先前存在的贫血、出血、盆腔炎以及腹部和盆腔疼痛会增加再次干预的风险。
对于 UF 患者,接受子宫肌瘤切除术、EA 和 UAE 治疗后的 5 年内,再次干预率估计值在 17%至 33%之间。在治疗选择时应考虑需要再次干预的风险。